07:00 EST Jazz Pharmaceuticals (JAZZ) to acquire Chimerix (CMRX) for $8.55 per share in cash
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Biotech Alert: Searches spiking for these stocks today
- Jazz Pharmaceuticals Reports Record Revenue Amid Growth Challenges
- Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
- Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Cost Management and Positive Market Developments
- Jazz Pharmaceuticals Faces DEI Challenges Amidst Executive Order and Growing Scrutiny